Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study

NCT03456830 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT03456830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03456830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
May 21, 2018
Completion date
October 28, 2019
Enrollment
115 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

enteric hyperoxaluria